Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Ther Adv Med Oncol
2016 May 01;83:188-97. doi: 10.1177/1758834016630976.
Show Gene links
Show Anatomy links
Nintedanib in NSCLC: evidence to date and place in therapy.
Bronte G
,
Passiglia F
,
Galvano A
,
Barraco N
,
Listì A
,
Castiglia M
,
Rizzo S
,
Fiorentino E
,
Bazan V
,
Russo A
.
???displayArticle.abstract???
The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.
Borghaei,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
2015, Pubmed
Borghaei,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
2015,
Pubmed
Brahmer,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
2015,
Pubmed
Bronte,
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
2016,
Pubmed
Bronte,
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
2010,
Pubmed
Bronte,
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
2014,
Pubmed
Doebele,
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
2012,
Pubmed
Ellis,
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
2010,
Pubmed
Folkman,
What is the evidence that tumors are angiogenesis dependent?
1990,
Pubmed
Garon,
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
2014,
Pubmed
Garon,
Pembrolizumab for the treatment of non-small-cell lung cancer.
2015,
Pubmed
Gettinger,
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
2015,
Pubmed
Herbst,
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
2010,
Pubmed
Hilberg,
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
2008,
Pubmed
Huang,
Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
2015,
Pubmed
Jackson,
HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.
2010,
Pubmed
Kutluk Cenik,
BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
2013,
Pubmed
Li,
Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
2014,
Pubmed
Lopez-Chavez,
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
2012,
Pubmed
Mross,
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
2010,
Pubmed
Novello,
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
2015,
Pubmed
Okamoto,
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
2015,
Pubmed
Onimaru,
Angiogenic and lymphangiogenic cascades in the tumor microenvironment.
2011,
Pubmed
Osarogiagbon,
Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.
2015,
Pubmed
Pallis,
Targeting tumor neovasculature in non-small-cell lung cancer.
2013,
Pubmed
Passiglia,
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
2015,
Pubmed
Paz-Ares,
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
2012,
Pubmed
Paz-Ares,
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
2013,
Pubmed
Peters,
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
2012,
Pubmed
Piperdi,
Targeting angiogenesis in squamous non-small cell lung cancer.
2014,
Pubmed
Reck,
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
2014,
Pubmed
Reck,
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
2015,
Pubmed
Rolfo,
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014,
Pubmed
Rolfo,
BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
2013,
Pubmed
Roth,
Nintedanib: from discovery to the clinic.
2015,
Pubmed
Scagliotti,
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
2010,
Pubmed
Scagliotti,
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
2012,
Pubmed
Scagliotti,
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
2012,
Pubmed
Shepherd,
Erlotinib in previously treated non-small-cell lung cancer.
2005,
Pubmed
Vale,
Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.
2015,
Pubmed
Villaruz,
The role of anti-angiogenesis in non-small-cell lung cancer: an update.
2015,
Pubmed
Zhao,
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
2014,
Pubmed
de Boer,
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
2011,
Pubmed
